CHILKA RAWAL: Open Payments
NPI 1962656918 · TEANECK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,156 in 122 payments from 21 companies in 2025. Trend: 2023 $1,701 · 2024 $1,576 · 2025 $2,156
Food & beverage: $2,067Education: $90
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 25 | $465 |
| GlaxoSmithKline, LLC. | 22 | $316 |
| Optinose US, Inc. | 5 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $176 |
| Novartis Pharmaceuticals Corporation | 9 | $151 |
| CSL Behring | 8 | $116 |
| SANOFI-AVENTIS U.S. LLC | 1 | $90 |
| Regeneron Healthcare Solutions, Inc. | 5 | $85 |
| Grifols USA, LLC | 5 | $79 |
| Ionis Pharmaceuticals, Inc. | 4 | $75 |
Products named: DUPIXENT, Xhance, NUCALA, TRELEGY ELLIPTA, CUVITRU, Rhapsido, Xolair, EBGLYSS.
Industry payments across NJ — which companies pay providers there.
